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Abstract
Background: Although the majority of thyroid nodules are benign the process of excluding malignancy is
challenging and sometimes involves unnecessary surgical procedures. We explored the development of a predictive
model for malignancy in thyroid nodules by integrating a combination of simple demographic, biochemical, and
ultrasound characteristics.
Methods: Retrospective case-record review.
We reviewed records of patients with thyroid nodules referred to our institution from 2004 to 2011 (n = 536;
female 84 %, mean age 51 years). All malignancy was proven histologically while benign disease was either
confirmed histologically, or on cytology with minimum 36-month observation period. We focused on the
following predictors: age, sex, smoking status, thyroid hormones (FT4 and TSH) and nodule characteristics on
ultrasound. Variables were included in a multivariate logistic regression and bootstrap analyses were used to
confirm results.
Results: Independent predictors of malignancy in the fully adjusted model were TSH (OR 1.53, 95 % CI 1.10, 2.12, p= 0.01),
male gender (OR 3.45, 95 % CI 1.33, 8.92, p = 0.01), microcalcifications (OR 6.32, 95 % CI 2.82, 14.1, p < 0.001), and
irregular nodule margins (OR 5.45, 95 % CI 1.61, 18.6, p = 0.006) Bootstrap analyses strengthened these associations and
a parsimonious analysis consisting of these variables and age-group demonstrated an area under the curve of 0.77. A
predictive score was sensitive (86.9 %) at low scores and highly specific (94.87 %) at higher scores for distinguishing
benign from malignant disease.
Conclusions: A predictive model for malignancy using a combination of clinical, biochemical, and radiological
characteristics may support clinicians in reducing unnecessary invasive procedures in patients with thyroid nodules.
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Background
Thyroid cancer is the most common endocrine malig-
nancy accounting for more deaths than all other endo-
crine cancers combined [1]. The incidence of thyroid
cancer has continued to increase worldwide, partly due
to greater diagnostic activity, as well as a true increase in
disease occurrence [2, 3]. The differentiated thyroid can-
cers, papillary and follicular, are the most prevalent
histological types with papillary cancer accounting for
40–70 % of all cases of thyroid cancer [1]. In recent
years small papillary microcarcinomas, less than one cm
in size, are now increasingly detected due to the growing
use of modern imaging techniques such as ultrasound,
computerised tomography or positron emission tomog-
raphy (PET) scans [4]. Although differentiated thyroid
cancers generally carry a favourable prognosis affected
individuals suffer considerable morbidity, both from the
disease as well as from side effects of therapy. In most
instances treatment with thyroidectomy and radioactive
iodine ablation will incur the need for lifelong thyroid
hormone therapy [5].
Patients with thyroid cancer commonly present with clin-
ically or radiologically detectable thyroid nodules [6, 7].
The prevalence of palpable thyroid nodules is estimated at
about 4-7 % of the adult population in iodine-sufficient
areas [6] with higher figures reported in women, older pa-
tients, and in studies based on ultrasound scan examination
[6–8]. Yet despite the high frequency of thyroid nodules
only about 5–10 % of such nodules are malignant [6, 7].
Fine needle aspiration biopsy (FNAB) and histology is the
gold standard for diagnosing thyroid cancer but up to 25 %
of biopsies performed in practice are non-diagnostic [9].
Patients with non-diagnostic biopsies often undergo repeat
biopsies and in some cases proceed to a diagnostic thyroid-
ectomy with its accompanying risks of permanent hypo-
parathyroidism and recurrent laryngeal nerve damage [10].
The challenge for the clinician is thus to predict
which thyroid nodules are malignant as patients with
benign nodules can be spared unnecessary interven-
tion. A number of simple clinical characteristics have
traditionally been associated with an increased malig-
nancy risk including male gender, age < 30 years or
>60 years, a family history of thyroid cancer, previous
exposure to head and neck irradiation, and a firm,
hard, rapidly enlarging nodule with compressive
symptoms such as dysphagia, dysphonia and breath-
lessness [6]. Ultrasound examination of the thyroid is
also a useful adjunct to clinical assessment, and nod-
ule characteristics that carry a high risk of malignancy
include hypoechogenicity, microcalcifications, irregular
margins, solid composition, and single nodularity [11].
However when considered individually none of these
features are sufficiently sensitive to guide clinical
decisions [12].
In recent years serum thyrotropin (TSH) has emerged
as an independent predictor of malignancy in patients
with thyroid nodules [13, 14]. TSH is a thyroid growth
factor and in animal experiments stimulates thyroid cell
proliferation through cyclic AMP mediated pathways,
thereby promoting thyroid malignancy [15]. Further-
more, levothyroxine-induced TSH suppression remains
a therapeutic cornerstone for preventing cancer recur-
rence following thyroidectomy and radioactive iodine
treatment [16]. In observational studies a direct relation-
ship has been shown between TSH concentrations and
thyroid cancer risk and other adverse outcomes even at
TSH levels within the euthyroid range [17, 18]. In
addition increased TSH concentration is associated with
a more advanced stage of thyroid cancer at presentation
[19] adding credence to its pivotal role in the develop-
ment and progression of thyroid cancer.
Thus, the prediction of thyroid cancer in patients with
thyroid nodules involves multiple clinical, biochemical,
and radiological risk factors and a predictive model is
unlikely to be satisfactorily achieved by a single set of
predictors. While most studies to date have focused on
single risk factors, whether clinical, radiological, or bio-
chemical, only a few studies have evaluated these factors
in combination. A robust predictive model incorporating
a combination of simple easily obtainable clinical, la-
boratory and radiological risk factors may offer adequate
sensitivity to serve as a pragmatic decision aid to sup-
port clinicians in practice. The aim of this study there-
fore was to explore the potential of developing a
predictive model for the risk of thyroid cancer in pa-
tients with thyroid nodules using demographic, clinical,
laboratory and ultrasound predictors.
Methods
Patients
We retrospectively reviewed the records of patients re-
ferred for evaluation of thyroid nodules at our institution
between January 2004 and December 2011. Patients with
thyroid nodules were identified from histopathology re-
cords (n = 602). We excluded patients with inadequate
clinical or laboratory information and patients in whom
a final diagnosis was not reached (n = 66). All diagnoses
of malignancy were proven histologically after thyroidec-
tomy or surgical biopsy (n = 50). Benign disease was ei-
ther confirmed histologically in patients following
thyroidectomy or surgical biopsy (n = 362) or was based
on a negative fine needle aspiration cytology and a mini-
mum clinical observation period of 36 months in those
who did not undergo surgery (n = 124). We evaluated
the following candidate predictors: age, gender, smoking
status, thyroid hormone status i.e. serum free thyroxine
(FT4) and serum TSH, and thyroid ultrasound charac-
teristics (hypoechogenicity, microcalcifications, irregular
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margins, spherical shape, and single nodularity and solid
composition). Approval to undertake the study was re-
ceived from the NHS Research and Ethics Committee
for Wales (reference 12/WA/0334) and the Cwm Taf
University Health Board Research and Development
Office (reference CT/278/101463/12).
Statistical analysis
To select suitable predictors in the model all apriori
candidate predictors were entered initially into a univari-
ate analysis and then all variables were included in a
multivariate logistic regression to analyse the odds of de-
veloping malignancy. The relevant factors and their
weighting were then built into a final model. TSH and
FT4 levels were categorized into tertiles. As the risk of
malignancy is increased in young adults as well as the
elderly we coded age as 1 if the age was less than
30 years or more than 60 years while patients aged 30–
60 years were coded as 0. Smokers were defined as never
smoked, previous smokers, or current smokers. Ultra-
sound characteristics such as size, echogenicity and nod-
ule composition were utilised as ordered categorical
variables. Logistic regression was undertaken to assess
the odds of malignancy for each of these variables. In
addition we explored for interaction between TSH level
and age-group and TSH and gender using likelihood ra-
tio tests. We then modelled in a parsimonious approach
all variables associated with malignancy in univariate or
multivariate analysis maintaining age-group and gender
as forced variables. Confirmatory bootstrap analysis was
undertaken with 1000 iterations using age-group and
gender as strata. These variables were taken forward for
area under the receiver operating characteristic (ROC)
using the “lroc” command in STATA. A risk score was
then generated based on identified associations and the
magnitude of their effect. All statistical analysis was
undertaken using STATA version 12 (STATACORP,
College Station, TX, USA).
Results
Baseline characteristics
We identified 602 patients from the thyroid histopatho-
logical records. Of these, 48 (8 %) did not have a final
cytological or histological diagnosis and clinical records
were irretrievable in 18 (3 %) patients leaving a final
sample size of 536 for analysis. Data on smoking was
missing for 81 individuals while 22 individuals had miss-
ing data for TSH. The baseline characteristics of these
patients is summarised in Table 1. As expected the ma-
jority of our cohort was female, young to middle age,
with a 9 % malignancy detection rate. The histological
subtypes comprised papillary (69 %), follicular (8 %),
hurtle cell (4 %), anaplastic (6 %), lymphoma (6 %), and
medullary cancer (6 %). Of the 536 patients 70 (13 %)
had indeterminate cytology including atypical cytology
(Thy3a) and suspected follicular neoplasm (Thy3f ) [5];
of these 5 patients (7 %) had a final diagnosis of
malignancy.
Predictors of malignancy
Independent predictors of malignancy in the fully ad-
justed model were TSH group (OR 1.53, 95 % CI 1.10,
2.12, p = 0.01), male gender (OR 3.45, 95 % CI 1.33,
8.92, p = 0.01), the presence of microcalcifications (OR
6.32, 95 % CI 2.82, 14.1, p < 0.001), and irregular mar-
gins (OR 5.45, 95 % CI 1.61, 18.6, p = 0.006) (Table 2).
The association between TSH levels and malignancy was
only marginally attenuated when adjusting for FT4. In this
relationship, we found no evidence of interaction between
TSH levels and age-group (p = 0.91) or gender (p = 0.64).
Bootstrap analysis confirmed the key associations with all
associations remaining statistically significant (Table 3). A
parsimonious analysis consisting variables associated with
malignancy and forced variables demonstrated an area
under the curve of 0.77 (Additional file 1: Figure S1).
Score generation
Based on our above analysis we generated a score to pre-
dict malignancy. We used TSH > 2.5 = 1, Age-group <30
or >60 = 1, presence of microcalcification = 2, male gen-
der = 2, irregular nodule margins = 2, mixed echogeni-
city = 1, and hypoechogenicity = 2. Overall, scores >4
were highly sensitive (86.9 %) whereas >7 were highly
specific (94.87 %) for malignancy (Table 4). Out of 70
patients with indeterminate cytology, 40 patients (57 %)
had a score of 2 or less of which 2 patients (5 %) had a
final diagnosis of malignancy while 21 patients (30 %)
with a score of 1 or less all had a final diagnosis of
benign nodules. Thus in patients with indeterminate cy-
tology, the negative predictive value of a score of 2 or
less was 95–100 %.
Discussion
As in other countries we have previously reported an in-
crease in the incidence of thyroid cancer in Wales, a
trend which appears predominantly driven by the grow-
ing detection of papillary thyroid cancers [20]. In parallel
we have also seen a steady increase in the number of
thyroid surgical procedures performed for malignant
thyroid disease in the same population [21]. The patient
with a thyroid nodule thus presents a challenge as it is
crucial to accurately identify the small proportion of
malignant cases and at the same time avoid subjecting
individuals with benign nodules to unwarranted surgical
interventions with lifelong repercussions. A robust pre-
dictive model for malignancy could therefore support
clinicians and patients in arriving at an informed deci-
sion regarding the urgency and scope of intervention
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especially where FNAB is considered inconclusive or in-
adequate for analysis.
Our multivariate analysis confirms some well-established
risk factors for thyroid malignancy including male gender,
TSH > 2.5 mU/L, and typical ultrasound characteristics of
microcalcification, irregular nodule margin, and solid nod-
ule composition [22]. However, we found no association be-
tween age (<30 or >60 years) and risk of malignancy. The
reason for this is unclear but may indicate a changing epi-
demiology with increasing detection of thyroid cancer
Table 2 Odds Of Malignancy In Univariate And Multivariate Analyses
Univariate analysis (n = 536) Multivariate analysis (n = 422)
Variable OR (95%CI) pa OR (95%CI) pa
TSH – upper tertile 1.52 (1.19, 1.92) 0.001 1.53 (1.10, 2.12) 0.01
FT4 - upper tertile 0.82 (0.66, 1.02) 0.08 0.84 (0.61, 1.15) 0.28
Age-group (<30 or > 60 yrs) 1.16 (0.64, 2.09) 0.62 1.17 (0.51, 2.71) 0.71
Male gender 3.83 (2.04, 7.17) <0.001 3.45 (1.33, 8.92) 0.01
Smoker 0.93 (0.64, 1.38) 0.75 1.02 (0.65, 1.60) 0.93
Size group 0.79 (0.55, 1.15) 0.23 0.78 (0.45, 1.37) 0.40
Microcalcification 7.55 (4.07, 14.0) <0.001 6.32 (2.82, 14.1) <0.001
Nodularity 1.09 (0.59, 2.01) 0.78 0.79 (0.36, 1.76) 0.57
Hypo-echogenicity 1.52 (1.09, 2.10) 0.01 1.17 (0.73, 1.89) 0.51
Irregular margins 4.49 (1.76, 11.4) 0.002 5.45 (1.61, 18.6) 0.006
Solid composition 1.24 (0.82, 1.87) 0.31 1.05 (0.62, 1.77) 0.84
aCalculated using the Wald Test; Multivariate analysis is analysis adjusted for all variables shown in this table
Table 1 Baseline characteristics of patients
Characteristics Benign Malignant Total
Number 486 50 536 (100 %)
Male sex (%) 67 (13.8 %) 19 (38.0 %) 86 (16.0 %)
Age (years) 51.2 (15.9) 50.9 (15.9) 51.2 (15.9)
Smoking status
Never 240 (57.4 %) 23 (62.1 %) 263 (57.8 %)
Previous 53 (12.7 %) 3 (8.11 %) 56 (12.3 %)
Current 125 (29.9 %) 11 (29.7 %) 136 (29.9 %)
Thyroid status
TSH (mU/l) 1.20 (0.50–2.00) 1.95 (1.13–2.90) 1.40 (0.70–2.40)
FT4 (pmol/l) 15.8 (7.52) 13.8 (5.38) 16.9 (7.56)
Nodule size (cm) 2.91 (1.63) 2.99 (1.44) 2.91 (1.61)
Microcalcification 61 (12.5 %) 26 (52.0 %) 87 (16.2 %)
Nodule Composition
Cystic 90 (18.5 %) 6 (12.0 %) 96 (17.9 %)
Mixed 53 (10.9 %) 6 (12.0 %) 59 (11.0 %)
Solid 343 (70.6 %) 38 (76.0 %) 381 (71.1 %)
Echogenicity
Iso or hyper-echoic 332 (68.3 %) 25 (50.0 %) 357 (66.6 %)
Mixed 59 (12.1 %) 9 (18.0 %) 68 (12.7 %)
Hypo-echoic 95 (19.6 %) 16 (32.0 %) 111 (20.7 %)
Margins
Regular 469 (96.5 %) 43 (86.0 %) 512 (95.5 %)
Irregular 17 (3.50 %) 7 (14.0 %) 24 (4.5 %)
Figures are mean (SD), number (%) or median (IQR)
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across all ages as shown in recent surveys from our popula-
tion and others [20, 23]. Thus the majority of the power for
prediction was derived from the thyroid ultrasound findings
although the inclusion of TSH and gender further im-
proved the model.
Using a scoring system of 2-10 we were able to stratify
the risk of malignancy in patients presenting with thy-
roid nodules. Our score had high specificity (95 %) at
high levels (>7) but only a small proportion (4 %) of our
cohort fell into this category. Nonetheless our score
would be particularly useful for risk stratification in indi-
viduals with inconclusive FNAB or where invasive inves-
tigations are considered unduly intrusive such as in the
frail, elderly, or in pregnancy. In such scenarios higher
scores would dictate an aggressive approach while lower
scores would support clinicians in adopting a more
conservative or “wait and watch” policy. In our sample a
score of 2 or less was associated with a low probability
of disease in patients with indeterminate cytology
(negative predictive value 95–100 %) and thus low scor-
ing individuals with indeterminate cytology could have
been safely managed conservatively.
A number of studies have developed predictive models
for thyroid cancer in patients with thyroid nodules using
a variety of approaches. Stojadinovic et al used Bayesian
analysis to build a clinical decision aid based on a pro-
spective analysis of 216 patients with thyroid nodules
who underwent thyroidectomy [24]. Their model incor-
porated nodule size, FNAB cytology, and ultrasound
characteristics, and was highly predictive of malignancy
(AUC 0.88, 95 % CI; 0.82-0.94). However this model was
also based on the technique of electrical impedance
scanning which is not routinely available in practice
[24]. Other studies utilising similar Bayesian principles
have reported various combinations of clinical and sono-
graphic predictors such as age, gender, and ultrasound
characteristics [25, 26]. One study utilised a classification
and regression tree (CART) classifier in a two-stage
model (sensitivity 80 %, specificity 94.1 %) that included
age, sex, and nodule size in the first stage and echogeni-
city and microcalcifications in the second stage [27].
Another approach used by others has been to develop
risk stratification algorithms derived from multivariate
analysis. Boelaert and co-workers calculated a predictive
formula for malignancy in patients with nodules, using
age, gender, goitre type, and serum TSH [14]. In their
study a TSH in the upper third of the normal range was
significantly associated with malignancy (OR 2.91 95 % CI
1.49, 5.71) [14]. By means of a regression model Maia et al
showed a strong risk of malignancy in patients aged
>39 years and in those with suspicious ultrasound features
(predictive accuracy, 81.7 %) [28]. Similar findings were
reported in another study restricted to individuals with in-
determinate or suspicious FNABs [29]. Elsewhere, Nixon
et al applied 8 predictor variables including TSH,
ultrasound characteristics, and FNA cytology to cre-
ate a nomogram with a high discriminatory ability
(concordance index, 91 %) [30]. One mathematical for-
mula derived from ultrasound characteristics alone proved
reliable for detecting non-follicular neoplasms (sensitivity,
86.5 %, specificity 92.3 %) [31]. However the utility of
complex calculations and algorithms in busy clinical set-
tings is still unclear.
The strength of our study lies in the simplicity and
practical appeal of our predictive score as an office based
tool derived from a combination of easily obtainable
Table 3 Odds of malignancy using a parsimonius approach with confirmatory bootstrap analysis
Multivariate Analysis (N = 514) Bootstrap analysis (N = 514)
Variable Odds Ratio (95%CI) pa Odds Ratio (95%CI) pa
TSH – upper tertile 1.65 (1.28, 2.14) <0.001 1.65 (1.28, 2.13) <0.001
Age-group <30 or >60 years 1.20 (0.60, 2.37) 0.61 1.20 (0.57, 2.47) 0.63
Male gender 4.41 (2.06, 9.46) <0.001 4.41 (1.97. 9.89) <0.001
Microcalcification 7.33 (3.62, 14.8) <0.001 7.33 (3.35, 16.1) <0.001
Echogenicity 1.24 (0.82, 1.86) 0.30 1.24 (0.80, 1.91) 0.34
Irregular margins 3.18 (1.05, 9.63) 0.04 3.18 (0.95, 10.6) 0.06
aCalculated using the Wald Test, Multivariate analysis is analysis adjusted for all variables shown in this table
Table 4 Sensitivity, specificity and correct classifaction of
malignancy based on predictive score
Cut-point Sensitivity Specificity Correctly Classified LR+ LR-
(> = 2) 100 % 0.00 % 8.95 % 1.00
(> = 3) 93.48 % 28.21 % 34.05 % 1.30 0.23
(> = 4) 86.96 % 52.78 % 55.84 % 1.84 0.25
(> = 5) 65.22 % 72.65 % 71.98 % 2.38 0.48
(> = 6) 45.65 % 87.82 % 84.05 % 3.75 0.62
(> = 7) 28.26 % 94.87 % 88.91 % 5.51 0.76
(> = 8) 23.91 % 97.86 % 91.25 % 11.19 0.78
(> = 9) 13.04 % 99.15 % 91.44 % 15.26 0.88
(> = 10) 4.35 % 99.79 % 91.25 % 20.35 0.96
The positive likelihood ratio (LR+) is the ratio of the probability of a positive
test among the truly positive subjects to the probability of a positive test
among the truly negative subjects. The negative likelihood ratio (LR–) is the
ratio of the probability of a negative test among the truly positive subjects to
the probability of a negative test among the truly negative subjects
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predictors. As a decision aid our score could inform cli-
nicians and potentially limit the number of unnecessary
invasive procedures undertaken in low-risk individuals
with inconclusive or inadequate FNABs. Furthermore
our data, sourced from a relatively large clinic popula-
tion, is representative of patients with thyroid nodules
encountered in everyday practice. The malignancy rate
of 9 % in our sample is consistent with the prevalence of
malignancy in secondary care referral settings. However
our study has some limitations. Although all cases of
malignancy were diagnosed by surgical specimen hist-
ology some individuals with benign disease did not
undergo surgery but relied on the FNAB and a three
year clinical observation period for the final diagnosis.
Nonetheless this approach reduced surgical selection
bias allowing us to analyse a broader spectrum of pa-
tients with a greater percentage of low risk individuals.
Data were not available on anti-TPO antibody status for
the majority in patients therefore this was not included
in models. Lastly our data was retrospective and will
have to be considered preliminary pending confirmation
in an externally validated prospective cohort.
Conclusion
In conclusion a predictive model for malignancy using a
combination of simple accessible clinical, biochemical,
and sonographic predictors could improve the manage-
ment of thyroid nodules by supporting clinicians in re-
ducing invasive surgical procedures in low risk patients
with thyroid nodules.
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Additional file 1: Figure S1. Area under the curve for model
predicting malignancy. Area under ROC curve = 0.7667 (PDF 14 kb)
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